1. Sex Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation Among People With Human Immunodeficiency Virus in the United States
- Author
-
Zanni, Markella V, Foldyna, Borek, McCallum, Sara, Burdo, Tricia H, Looby, Sara E, Fitch, Kathleen V, Fulda, Evelynne S, Autissier, Patrick, Bloomfield, Gerald S, Malvestutto, Carlos D, Fichtenbaum, Carl J, Overton, Edgar T, Aberg, Judith A, Erlandson, Kristine M, Campbell, Thomas B, Ellsworth, Grant B, Sheth, Anandi N, Taiwo, Babafemi, Currier, Judith S, Hoffmann, Udo, Lu, Michael T, Douglas, Pamela S, Ribaudo, Heather J, and Grinspoon, Steven K
- Subjects
Biomedical and Clinical Sciences ,Immunology ,Infectious Diseases ,Prevention ,Atherosclerosis ,Heart Disease ,Cardiovascular ,Clinical Research ,Clinical Trials and Supportive Activities ,Good Health and Well Being ,Humans ,Female ,Male ,United States ,HIV ,Sex Characteristics ,1-Alkyl-2-acetylglycerophosphocholine Esterase ,Plaque ,Atherosclerotic ,Risk Factors ,Inflammation ,Biomarkers ,Coronary Artery Disease ,coronary atherosclerosis ,inflammation ,women ,reproductive aging ,Biological Sciences ,Medical and Health Sciences ,Microbiology ,Clinical sciences - Abstract
BackgroundAmong people with HIV (PWH), sex differences in presentations of atherosclerotic cardiovascular disease (ASCVD) may be influenced by differences in coronary plaque parameters, immune/inflammatory biomarkers, or relationships therein.MethodsREPRIEVE, a primary ASCVD prevention trial, enrolled antiretroviral therapy (ART)-treated PWH. At entry, a subset of US participants underwent coronary computed tomography angiography (CTA) and immune phenotyping (n = 755 CTA; n = 725 CTA + immune). We characterized sex differences in coronary plaque and immune/inflammatory biomarkers and compared immune-plaque relationships by sex. Unless noted otherwise, analyses adjust for ASCVD risk score.ResultsThe primary analysis cohort included 631 males and 124 females. ASCVD risk was higher among males (median: 4.9% vs 2.1%), while obesity rates were higher among females (48% vs 21%). Prevalence of any plaque and of plaque with either ≥1 visible noncalcified portion or vulnerable features (NC/V-P) was lower among females overall and controlling for relevant risk factors (RR [95% CI] for any plaque: .67 [.50, .92]; RR for NC/V-P: .71 [.51, 1.00] [adjusted for ASCVD risk score and body mass index]). Females showed higher levels of IL-6, hs-CRP, and D-dimer and lower levels of Lp-PLA2 (P < .001 for all). Higher levels of Lp-PLA2, MCP-1, and oxLDL were associated with higher plaque (P < .02) and NC/V-P prevalence, with no differences by sex. Among females but not males, D-dimer was associated with higher prevalence of NC/V-P (interaction P = .055).ConclusionsAmong US PWH, females had a lower prevalence of plaque and NC/V-P, as well as differences in key immune/inflammatory biomarkers. Immune-plaque relationships differed by sex for D-dimer but not other tested parameters. Clinical Trial Registration. ClinicalTrials.gov; identifier: NCT0234429 (date of initial registration: 22 January 2015).
- Published
- 2023